n CME : Your SA Journal of CPD - Pharm info

Volume 21, Issue 11
  • ISSN : 0256-2170



Extracted from text ... PHARM INFO compared with Fosamax. Vasomotor symptoms were reported by 4% of patients on Fosamax and by 10% of patients on Evista (p = 0.01). The EFFECT trials were double-blind, randomised, 1-year studies conducted in 17 coun-tries. All patients in the study had osteoporosis as defined by a BMD score of 2.0 standard deviations or greater below young normal mean bone mass for either the lumbar spine or total hip. BMD was mea-sured in both groups at baseline and again at 6 and 12 months of treatment. All BMD measures were validated by a quality assurance centre and laborato-ry tests were performed by a central testing facility. All patients were at least 40 years ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error